BioSpace News Archive

Nektar Therapeutics presented preclinical data on its immuno-oncology pipeline candidates, bempegaldesleukin, a CD122-preferential IL-2 pathway agonist, and NKTR-255, an IL-15 receptor agonist, at the American Association for Cancer Research Annual Meeting 2019.

AmorChem, a leading venture fund dedicated to creating the next generation of biotech companies derived from academic research, introduced its rebranding this week.

Blueprint Medicines Corporation announced the closing of its previously announced underwritten public offering of 4,662,162 shares of its common stock at a public offering price of $74.00 per share, including the exercise in full by the underwriters of their option to purchase additional shares of common stock.

Interactive workshops and coursework grounded in experience and innovation science will provide leaders with customized approaches to create and sustain patient-centered cultures

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 12 new employees.

Presentations Highlight Syros’ Leadership in Selective CDK7 Inhibition as Potentially Transformative Targeted Approach for Difficult-to-Treat Cancers

Navidea Biopharmaceuticals, Inc. announced that Arash Kardan, M.D., will give an oral presentation on the results of the Company’s NAV3-21 clinical study at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting in June 2019.

JMP Group LLC, an investment banking and alternative asset management firm, announced that David Schechner has joined JMP Securities as a managing director in its healthcare investment banking group.

The Scalable Precision VR® Enterprise Solution Seamlessly Integrates into a Hospital’s Existing Workflow

Successful manufacturing and release of GMP vials of UCARTCS1